Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24461928 | 0.89 | EPHX1 (0.38) | MEN1KMT2AEPHX1 | |
| SCHEMBL28641303 | 0.89 | KDM4E (0.37) | MEN1KMT2AEPHX1 | |
| SCHEMBL10015688 | 0.89 | ALDH1A1 (0.33) | — | |
| SCHEMBL14868287 | 0.88 | EPHX1 (0.43) | EPHX1 | |
| SCHEMBL9973239 | 0.86 | EPHX1 (0.47) | EPHX1 | |
| SCHEMBL13227081 | 0.85 | EPHX1 (0.39) | MEN1KMT2AEPHX1 | |
| Hydrochloric Acid SCHEMBL1938197 | 0.84 | EPHX1 (0.45) | EPHX1 | |
| Hydrochloric Acid SCHEMBL1936229 | 0.84 | EPHX1 (0.45) | EPHX1 | |
| Hydrochloric Acid SCHEMBL1938993 | 0.84 | EPHX1 (0.45) | EPHX1 | |
| SCHEMBL25657787 | 0.83 | EPHX1 (0.48) | EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10668031-B2 | Biguanide compositions and methods of treating metabolic disorders | ANJI PHARMA (US) LLC (US) | 2020-06-02 | — | — | US | disclosed |
| US-20190076380-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | ANJI PHARMACEUTICALS INC. | 2019-03-14 | — | — | US | disclosed |
| US-20160115162-A1 | Radiosynthesis of Tau Radiopharmaceuticals | THE GENERAL HOSPITAL CORPORATION | 2016-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10668031-B2 | Biguanide compositions and methods of treating metabolic disorders | SLC5A2, SLC5A1, GPR119 | MEN1 679/4885KMT2A 2239/4885EPHX1 2097/4885 |
| US-20160115162-A1 | Radiosynthesis of Tau Radiopharmaceuticals | HTR7, MAPT, TSN | MEN1 214/4885KMT2A 2877/4885EPHX1 4550/4885 |
| US-20190076380-A1 | Biguanide Compositions and Methods of Treating Metabolic Disorders | SLC5A2, SLC5A1, GPR119 | MEN1 679/4885KMT2A 2239/4885EPHX1 2097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.